Ancora Heart, Inc news

Santa Clara, Calif.– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch^® Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System is designed to provide a minimally invasive t

Santa Clara, Calif.– June 30, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients with

Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch^® Ventricular Repair System in patients with reduced ejection fraction heart failure (HFrEF). This expansion allows Ancora Heart to double patient enrollmen

During the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, Santa Clara, CA-based Ancora presented interim study results from systolic heart failure patients treated with AccuCinch, a percutaneous therapy designed to improve left ventricular function.

A stronger and more experienced Ancora Heart entered into the 31st Transcatheter

Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation thi